Clinical Trials Logo

Psychotic Disorders clinical trials

View clinical trials related to Psychotic Disorders.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06315114 Recruiting - Mental Disorder Clinical Trials

A Transdiagnostic Mentalization-based Intervention for Parents With Mental Disorders

LIGHTHOUSE
Start date: March 11, 2024
Phase: N/A
Study type: Interventional

The aim of this randomised clinical trial is to evaluate the short and longterm effects of a transdiagnostic mentalization-based intervention (Lighthouse MBT Parenting Program) compared to care as usal (CAU) for parents with a mental disorder in adult mental health service.

NCT ID: NCT06314204 Recruiting - Clinical trials for Psychotic; Disorder, Cannabis

Impact of Cannabis Consumption on the Course, Modalities of Hospitalization and the Short-term Prognosis of Inpatients Suffering From Psychotic Symptoms

canhope
Start date: September 20, 2016
Phase:
Study type: Observational

Few studies have evaluated, in patients with symptomatology the impact of cannabis use on the duration of hospitalization and on short- and medium-term developments. The objective of this study will be to assess the impact of cannabis on the duration, the hospitalization and the short- and medium-term evolution of patients with psychotic symptoms and cannabis use. We hypothesize that these patients (in comparison with patients with psychotic symptomatology and not using cannabis) would be hospitalized more long, exposed to a higher risk of resistance to the usual therapeutics, would have a lack of therapeutic alliance and insight, relapses and hospitalizations more frequent, more marked negative symptoms and lower quality remission. They would also be more prone to impulsive and aggressive behaviour.

NCT ID: NCT06313918 Recruiting - Bipolar Disorder Clinical Trials

Exercise Therapy in Mental Disorders-study

Start date: September 27, 2023
Phase: N/A
Study type: Interventional

The study will compare standard high-intensity training with brief high-intensity training in people with schizophrenia-spectrum or bipolar disorder. The overall aim is to determine which of the two is superior in a long-term perspective.

NCT ID: NCT06278532 Recruiting - Schizophrenia Clinical Trials

Validation of the Lithuanian Version of the BNSS, CDSS, and the SCoRS

Start date: December 11, 2023
Phase:
Study type: Observational

This study aims to validate the Lithuanian version of the Brief Negative Symptoms Scale, Calgary Depression Scale for Schizophrenia, and Schizophrenia Cognition Rating Scale in a Lithuanian sample. This will be done by comparing results obtained from the Brief Negative Symptoms Scale, Calgary Depression Scale for Schizophrenia, and Schizophrenia Cognition Rating Scale with results obtained from the Positive and Negative Symptoms Scale, the Montgomery Asberg Depression Rating Scale, and the Montreal Cognitive Assessment test.

NCT ID: NCT06263933 Recruiting - Psychotic Episode Clinical Trials

Effect of Experience Sharing and Mutual Assistance on Insight and Recovery During the First Psychotic Episode

DIPEM
Start date: November 13, 2023
Phase: N/A
Study type: Interventional

Controlled, prospective, qualitative and quantitative trial. The goal of this trial is to evaluate the mutual assistance early intervention device efficacy and its impact on insight and personal recovery of participants living with a first psychotic episode. This intervention lasts 5 days with 1 session per day of 1 hour 30 minutes. Three evaluations, before the intervention, after intervention and 1 month after the hospitalization's end.

NCT ID: NCT06221852 Recruiting - Clinical trials for Schizoaffective Disorder

Ketogenic and Nutritional Interventions for First Episode Bipolar Disorder

Start date: March 5, 2024
Phase: N/A
Study type: Interventional

This is a randomized, controlled clinical trial to assess the effects of the ketogenic diet in combination with treatment as usual on brain energy metabolism and psychiatric symptoms in individuals with first episode bipolar disorder and schizoaffective disorder.

NCT ID: NCT06218979 Recruiting - Psychosis Clinical Trials

KF2022#3-trial: Effect of Tea and Cola Beverage on Absorption of Risperidone Oral Solution

KF2022#3
Start date: December 4, 2023
Phase: Phase 1
Study type: Interventional

Risperidone is widely used in the treatment of schizophrenia, bipolar disorder, and aggression associated with moderate or severe Alzheimer's dementia. In vitro studies have shown that constituents of tea and cola beverages can result in insoluble complex formation with risperidone, potentially reducing risperidone oral absorption. The purpose of this study is to investigate the effect of tea and cola beverage on the pharmacokinetics of risperidone oral solution. In an open three-phase, randomized, crossover study with 12 healthy volunteers, the subjects will receive a 1 mg dose of risperidone oral solution with either water, tea or cola beverage. Blood samples will be collected and risperidone's pharmacokinetics will be monitored up to 48 hours postdose. Primary endpoint is area under the plasma concentration-time curve of risperidone. Recruitment starting date is December 4, 2023.

NCT ID: NCT06207526 Recruiting - Psychotic Disorder Clinical Trials

Delusion Ideation in the Context of Everyday Life

DICE
Start date: April 6, 2023
Phase: N/A
Study type: Interventional

The project aims to investigate the feasibility and acceptability of a blended face-to-face and smartphone intervention for distressing thoughts and experiences in people with schizophrenia spectrum disorders. A secondary aim is to assess the outcomes of the intervention at baseline (T0) and post-intervention (T1) (single-arm feasibility design). The study design is primarily based on Bell et al.'s (2018, 2020) blended face-to-face and smartphone intervention for hallucinations. The participants receive four face-to-face therapy sessions, using a smartphone between sessions employing elements of Ecological Momentary Assessment (EMA) and Intervention (EMI).

NCT ID: NCT06197048 Recruiting - Schizophrenia Clinical Trials

Effect of Nutritional Counseling on Anthropometry and Biomarkers in Patients Diagnosed With Schizophrenia/Psychosis or Bipolar Affective Disorder

Start date: September 25, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to compare the effect of nutritional counseling versus no treatment in patients with schizophenia or bipolar affective disorder. The main question it aims to answer are: • Can nutritional counseling have a preventive effect on the development of cardiovascular disease in patients with schizophenia or bipolar affective disorder? Participants will meet a nutritionist at baseline to asess nutritional status, biochemical and anthropometric measurements. Then, half of the study population will receive nutritional counseling. After six weeks, the same baseline measurements will be repeated to examine any potential differences between the two groups. After the intervention, the control group will be offered the same counseling as the intervention group received during the study.

NCT ID: NCT06182787 Recruiting - Schizophrenia Clinical Trials

Development of a Model for Digital Monitoring of the Mental State of the Hospitalized Patient

Start date: May 18, 2022
Phase:
Study type: Observational [Patient Registry]

This study presents the development and validation of a unique Digital Experience Sampling Method (ESM) questionnaire specifically adapted for monitoring changes in the mental state of patients during psychiatric hospitalization. The questionnaire was carefully crafted through focus groups involving patients and clinical staff, ensuring its relevance and applicability to the unique characteristics of mental state changes in a hospitalization setting. To evaluate the validity of the ESM questionnaire, symptom severity trends obtained from the questionnaire will be compared with estimates derived from the Positive and Negative Syndrome Scale (PANSS) assessment. Data will be collected from 100 subjects over a 14-day psychiatric hospitalization period. In addition to the ESM questionnaire, smartwatch sensors will monitor physiological indicators. Feasibility and patient compliance will be assessed by examining patients' willingness to use the digital ESM questionnaires and the smartwatch sensors. The study will also cross-reference self-reported sleep quality and activity levels captured in the ESM questionnaires with objective physiological indicators and nursing staff reports, providing insights into the reliability of the patient-reported data. Furthermore, the study will evaluate the impact of the ESM data on clinical decision-making by physicians throughout the 14-day psychiatric hospitalization period. Patient satisfaction and satisfaction among the multidisciplinary team with the monitoring model will also be assessed. This research underscores the potential of digital technologies to enhance patient-centered care and facilitate informed treatment decisions in psychiatric hospitalization settings.